226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon acquired 226,618 Alumis shares worth approximately $6.4 million, representing about 0.18% of the company. Several other institutional investors also increased their positions.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $33.27, despite several recent target-price reductions and one sell rating.
• Alumis reported weaker-than-expected quarterly results, including an EPS loss of $1.11 versus the $0.77 consensus estimate and revenue of $1.66 million versus expectations of $3.65 million. The stock opened at $11.10, well below its 50-day and 200-day moving averages.

Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ:ALMS - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the company's stock, valued at approximately $6,377,000. Bank of New York Mellon Corp owned about 0.18% of Alumis at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALMS. Russell Investments Group Ltd. lifted its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock worth $26,000 after acquiring an additional 4,894 shares during the period. New York State Common Retirement Fund lifted its position in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock valued at $35,000 after purchasing an additional 7,467 shares during the period. KBC Group NV purchased a new stake in Alumis in the 1st quarter valued at approximately $42,000. Strs Ohio boosted its holdings in Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company's stock valued at $44,000 after purchasing an additional 1,500 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company's stock worth $47,000 after purchasing an additional 6,027 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Alumis from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright raised Alumis from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $25.00 to $15.00 in a report on Wednesday. Wells Fargo & Company cut their price objective on Alumis from $51.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday. Robert W. Baird set a $27.00 target price on shares of Alumis in a research report on Tuesday. Finally, Oppenheimer lowered their price target on shares of Alumis from $55.00 to $37.00 and set an "outperform" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $33.27.

Alumis Price Performance

Shares of ALMS stock opened at $11.10 on Friday. The firm's 50-day simple moving average is $25.33 and its 200-day simple moving average is $24.61. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35. The firm has a market cap of $1.44 billion, a P/E ratio of -2.88 and a beta of -0.81.

Alumis (NASDAQ:ALMS - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.34). The company had revenue of $1.66 million during the quarter, compared to analysts' expectations of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. Analysts expect that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Activity at Alumis

In related news, insider Mark Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the transaction, the insider owned 48,533 shares in the company, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sanam Pangali sold 1,364 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $35,968.68. Following the sale, the insider directly owned 9,747 shares of the company's stock, valued at approximately $257,028.39. This trade represents a 12.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is owned by corporate insiders.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright upgraded its rating on Alumis. The upgrade helped support an earlier rebound in the shares, although its effect was subsequently overshadowed by the lupus-trial news. Alumis Stock Rating Upgraded by HC Wainwright
• Positive Sentiment: Alumis will participate in several September investor conferences. These events could give management an opportunity to explain the clinical results, discuss its broader pipeline and outline its strategy for using biomarker data to identify potentially responsive lupus patients. Alumis to Participate in Upcoming September Investor Conferences
• Neutral Sentiment: Options activity was unusually high. Elevated options trading indicates increased investor positioning and volatility following the clinical announcement, but it does not establish a clear directional outlook. Alumis Target of Unusually Large Options Trading
• Negative Sentiment: Alumis’ Phase 2b lupus study missed its key endpoints. The mixed data for the company’s lead SLE treatment raised concerns about the drug’s efficacy and commercial prospects, triggering a sharp decline in the stock. Management’s potential biomarker-based development strategy may preserve a path forward, but it also adds uncertainty and could require additional clinical work. Alumis Lead Lupus Drug Missed Phase 2b Trial Endpoints
• Negative Sentiment: Guggenheim downgraded Alumis from Buy to Neutral after the trial setback. The downgrade reflects reduced confidence in the lupus program and likely contributed to continued selling pressure. Additional analyst commentary has focused on the implications of the clinical miss for valuation and the company’s pipeline. Alumis Downgraded at Guggenheim

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.